NCT06643091View on ClinicalTrials.gov

Nintedanib Treatment in Unicentric Castleman Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

May 1, 2030

Study Completion Date

September 1, 2030

Conditions
Castleman Disease
Interventions
DRUG

Nintedanib

Nintedanib150 mg twice a day for 6 months Or Nintedanib 100mg twice a day in case of dose adjustment Oral route (during meals)

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT06643091 - Nintedanib Treatment in Unicentric Castleman Disease | Biotech Hunter | Biotech Hunter